Revexepride HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125900

CAS#: Revexepride HCl

Description: Revexepride, also known as SSP-002358, is a 5-HT4 receptor agonist and a novel prokinetic that stimulates gastrointestinal motility, which has been suggested as a continued cause of symptoms in these patients. Clinical trials showed that revexepride was no more effective than placebo in controlling regurgitation in patients with GERD symptoms partially responsive to PPIs. Revexepride was well tolerated.

Chemical Structure

img
Revexepride HCl
CAS# Revexepride HCl
Instruction

Theoretical Analysis

MedKoo Cat#: 125900
Name: Revexepride HCl
CAS#: Revexepride HCl
Chemical Formula: C21H35Cl2N3O5
Exact Mass: 479.20
Molecular Weight: 480.427
Elemental Analysis: C, 52.50; H, 7.34; Cl, 14.76; N, 8.75; O, 16.65

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: Revexepride HCl   219984-49-3 (free base)  

Synonym: Revexepride monohydrochloride monohydrate; Revexepride HCl; Revexepride hydrate; Revexepride hydrochloride

IUPAC/Chemical Name: 4-amino-5-chloro-N-(((3S,4S)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl)methyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide hydrochloride hydrate

InChi Key: PBUJIMKARWFIMP-YUANJJMISA-N

InChi Code: InChI=1S/C21H32ClN3O4.ClH.H2O/c1-21(2)10-15-18(23)16(22)9-14(19(15)29-21)20(27)24-11-13-5-7-25(12-17(13)26)6-4-8-28-3;;/h9,13,17,26H,4-8,10-12,23H2,1-3H3,(H,24,27);1H;1H2/t13-,17+;;/m0../s1

SMILES Code: O.Cl.COCCCN1CC[C@@H](CNC(=O)C2=CC(Cl)=C(N)C3=C2OC(C)(C)C3)[C@H](O)C1

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 480.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pierce D, Corcoran M, Velinova M, Hossack S, Hoppenbrouwers M, Martin P. A
phase 1 randomized study evaluating the effect of omeprazole on the
pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride
(SSP-002358), in healthy adults. Drug Des Devel Ther. 2015 Feb 27;9:1257-68. doi:
10.2147/DDDT.S64621. eCollection 2015. PubMed PMID: 25767373; PubMed Central
PMCID: PMC4354395.


2: Shaheen NJ, Adler J, Dedrie S, Johnson D, Malfertheiner P, Miner P, Meulemans
A, Poole L, Tack J, Thielemans L, Troy S, Vakil N, Zerbib F, Ruth M. Randomised
clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal
reflux disease who have persistent symptoms despite PPI therapy. Aliment
Pharmacol Ther. 2015 Apr;41(7):649-61. doi: 10.1111/apt.13115. Epub 2015 Feb 19.
PubMed PMID: 25693609.


3: Tack J, Zerbib F, Blondeau K, des Varannes SB, Piessevaux H, Borovicka J, Mion
F, Fox M, Bredenoord AJ, Louis H, Dedrie S, Hoppenbrouwers M, Meulemans A, Rykx
A, Thielemans L, Ruth M. Randomized clinical trial: effect of the 5-HT4 receptor
agonist revexepride on reflux parameters in patients with persistent reflux
symptoms despite PPI treatment. Neurogastroenterol Motil. 2015 Feb;27(2):258-68.
doi: 10.1111/nmo.12484. Epub 2014 Dec 21. PubMed PMID: 25530111; PubMed Central
PMCID: PMC4681320.